Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Objective: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia. Patients and Methods: This is a single-center retrospective observational study. All patients who were hospitalized at De...

Full description

Bibliographic Details
Main Authors: Maroun E. Hayek, MD, Michael Mansour, MD, Harrison Ndetan, MPH, MD, PhD, Quentin Burkes, PharmD, Robert Corkern, MD, Ammar Dulli, MD, Reya Hayek, BS, Karim Parvez, MD, Satwinder Singh, MD
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2542454821000540

Internet

http://www.sciencedirect.com/science/article/pii/S2542454821000540

Similar Items